Healthcare is first in region to implant investigational device in patients with clogged arteries
March 4, 2013
/PRNewswire-USNewswire/ -- A dissolvable stent that opens clogged arteries in the heart has researchers at Scottsdale Healthcare encouraged that it may become a game changing technology for treating the symptoms of coronary artery disease (CAD), the most common type of heart disease.
, MD is the first physician in the western U.S. to successfully implant the investigational device into a heart patient as part of a new clinical trial enrolling patients at Scottsdale Healthcare.
The Absorb Bioresorbable Vascular Scaffold (BVS), made by healthcare company Abbott, is a small mesh tube made of polylactide, a material that is commonly used in medical implants such as dissolvable sutures. Absorb is coated with a medication which reduces inflammation and tissue growth to help prevent renarrowing of the artery.
The scaffold restores blood flow and provides support to the vessel until the artery can stay open on its own. It dissolves over time, potentially allowing the vessel to resume more natural function and movement.
The clinical trial is evaluating potential benefits of Absorb in comparison to the leading metallic drug eluting stent in patients with CAD, the most common cause of death for men and women in
the United States
. Absorb is authorized for sale in CE Mark countries and is available in
, parts of
, and parts of
"The bioresorbable scaffold represents a potential game changing technology for our patients with coronary artery disease," said Dr. Rizik. "The idea of moving away from permanent metal implants to literally disappearing implants is a quantum leap forward for our heart patients at Scottsdale Healthcare. The cardiology team of physicians, nursing staff and clinicians are extremely pleased to participate in the trial of this latest advancement to our community."